

Summit Therapeutics plc
("Summit" or the "Company")

EXERCISE OF OPTIONS

Oxford, UK, 24 March 2015 – Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and *C. difficile* infection, announces that on 23 March 2015 it received a notification of exercise in respect of options granted over 16,777 new ordinary shares in the Company at an exercise price of 65 pence per share and 10,607 new ordinary shares in the Company at an exercise price of 20 pence per share. Consequently the Company has issued and allotted 27,384 new ordinary shares in the Company.

An application has been made for the 27,384 new ordinary shares to be admitted to AIM and admission is expected to occur on or around 27 March 2015. Following this issue of equity above the Company's issued share capital will comprise of 60,982,581 ordinary shares of 1 penny each.

- END -

About Summit Therapeutics

Summit is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease Duchenne muscular dystrophy and the infectious disease *C. difficile* infection.

For more information, please contact:

Summit Therapeutics

Glyn Edwards / Richard Pye (UK office)
Erik Ostrowski (US office)

Tel: +44 (0)1235 443 951
+1 617 294 6607

Cairn Financial Advisers LLP

(Nominated Adviser)
Liam Murray / Tony Rawlinson

Tel: +44 (0)20 7148 7900

N+1 Singer

(Broker)
Aubrey Powell / Jen Boorer

Tel: +44 (0)20 7496 3000

MacDougall Biomedical Communications

(US media contact)
Michelle Avery

Tel: +1 781 235 3060
mavery@macbiocom.com

Peckwater PR

(Financial public relations, UK)
Tarquin Edwards

Tel: +44 (0)7879 458 364
tarquin.edwards@peckwaterpr.co.uk